Expert Says Neratinib-Associated Diarrhea Manageable in HER2+ Breast Cancer

Brandon Scalea
Published: Friday, May 10, 2019
Michel Velez, MD

Michel Velez, MD

Aggressive prophylactic intervention right at the initiation of neratinib (Nerlynx) therapy has eased the concern of diarrhea associated with the pan-HER TKI in patients with early-stage HER2-positive breast cancer, according to Michel Velez, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication